We are driven to make a difference for patients and those who care for them.
At the heart of everything we do at Syros is our dedication to advancing medicines that provide a profound benefit for patients with difficult-to-treat diseases.
The genes expressed - turned on, off, up or down - in any given cell determine its type and function. When genes are expressed at the wrong time or in the wrong amounts, it changes the function of a cell, leading to disease. Because gene expression is fundamental to the function of all cells, we believe our pioneering approach has identified targets with the potential to provide patients with a range of diseases the opportunity to live longer and enjoy a better quality of life.
We are advancing our clinical-stage drug candidate, tamibarotene, across two genomically defined patient populations in higher-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia (AML).
In addition, we seek out-license opportunities that maximize value for our partners and us. We are exploring out-license opportunities for our SY-5609 clinical program, an oral reversible CDK7 with best-in-class selectivity and potency, enabling broad development potential.
We invite you to learn more about our programs and ongoing clinical trials, as well as to explore a select list of resources for these diseases.
Conley Chee
Chief Executive Officer of Syros